1. Home
  2. DCOY vs NXTS Comparison

DCOY vs NXTS Comparison

Compare DCOY & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

HOLD

Current Price

$0.84

Market Cap

674.8K

Sector

Health Care

ML Signal

HOLD

Logo Nexentis Technologies Inc. Common Stock

NXTS

Nexentis Technologies Inc. Common Stock

SELL

Current Price

$1.72

Market Cap

699.8K

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
DCOY
NXTS
Founded
N/A
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
674.8K
699.8K
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
DCOY
NXTS
Price
$0.84
$1.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.8K
★ 145.4K
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $263,445.00
Revenue This Year
N/A
N/A
Revenue Next Year
$20.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.43
52 Week High
$67.68
$53.90

Technical Indicators

Market Signals
Indicator
DCOY
NXTS
Relative Strength Index (RSI) 28.56 55.71
Support Level $0.53 $1.28
Resistance Level $1.24 $1.66
Average True Range (ATR) 0.07 0.20
MACD 0.02 0.04
Stochastic Oscillator 0.00 51.92

Price Performance

Historical Comparison
DCOY
NXTS

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Share on Social Networks: